ArticleAnnals of surgical oncology2026
Impact of Concomitant Proton Pump Inhibitor Use on Oncologic Outcomes of Neoadjuvant Chemoimmunotherapy in Locally Advanced Gastric Cancer: A Multicenter Real-World Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNeoadjuvant chemoimmunotherapy (NCIT) is an important treatment strategy for locally advanced gastric cancer (LAGC). Although proton pump inhibitors (PPIs) are frequently prescribed in oncology settings, their impact on the efficacy of perioperative immunotherapy remains unclear. PATIENTS AND
methodsThis multicenter retrospective cohort study included 107 patients with LAGC who received NCIT followed by curative-intent gastrectomy (January 2020‒December 2023). Patients receiving potassium-competitive acid blockers were included in the PPI group. Clinicopathological characteristics, pathological response, disease-free survival (DFS), and overall survival (OS) were compared, and multivariable Cox regression models identified independent prognostic factors.
resultsThe PPI group comprised 48 (44.9%) patients. Baseline characteristics were generally balanced between groups. PPI exposure was associated with significantly reduced nodal clearance, reflected by a lower ypN0 rate (47.9% versus 67.8%, p = 0.038). After a median follow-up of 33.0 months, DFS and OS were significantly worse in PPI-treated patients. Median DFS was 40.0 months (95% confidence interval [CI], 22.9-57.0) in the PPI group and not reached in the non-PPI group (p = 0.001). Multivariable analysis identified PPI exposure as an independent predictor of inferior DFS (hazard ratio [HR] 2.60; p = 0.033) and OS (HR 4.41; p = 0.007).
conclusionsConcomitant PPI exposure during NCIT was associated with impaired pathological nodal response and worse long-term survival in patients with LAGC. Given the retrospective design and limited data on exposure timing and duration, these findings should be considered hypothesis-generating and should not be interpreted as evidence of a duration-dependent or causal effect.
Indexed as
Identifiers
42251208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.